Advertisement


Lisa A. Carey, MD, and Maki Tanioka, MD, on HER2+ Breast Cancer: Results From the CALGB 40601 Alliance Trial

2016 San Antonio Breast Cancer Symposium

Advertisement

Lisa A. Carey, MD, and Maki Tanioka, MD, both of the University of North Carolina, discuss study findings on weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (Abstract S3-05).



Related Videos

Breast Cancer

Aleix Prat, MD, PhD, on HER2-Positive Breast Cancer: First Results of the PAMELA Trial (Spanish Language Version)

Aleix Prat, MD, PhD, of the University of Barcelona, discusses in Spanish study findings on intrinsic subtype as a predictor of pathologic complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer (Abstract S3-03).

Breast Cancer

Rowan T. Chlebowski, MD, PhD, on Diet and Breast Cancer: Trial Results

Rowan T. Chlebowski, MD, PhD, of the David Geffen School of Medicine at UCLA, discusses findings from the Women’s Health Initiative Dietary Modification study on low-fat diet and breast cancer overall survival (Abstract S5-04).

Cost of Care
Global Cancer Care
Breast Cancer

Peter Bach, MD, on The Global Cost of Cancer Care

Peter Bach, MD, of Memorial Sloan Kettering Cancer Center, summarizes his plenary lecture on drug costs and their effect on the affordability of cancer care worldwide (Plenary Lecture 3).

Breast Cancer

Lisa A. Carey, MD, on SABCS Meeting Highlights: Expert Perspective

Lisa A. Carey, MD, of the University of North Carolina, discusses a session she moderated on key data presented at SABCS, and gives her expert views on putting the research data into clinical practice.

Breast Cancer

Mothaffar Rimawi, MD, on HR-Positive, HER2-Positive Breast Cancer: Results of the NRG Oncology/NSABP B-52 Trial

Mothaffar Rimawi, MD, of the Smith Breast Center at Baylor College of Medicine, discusses phase II findings from a study evaluating pathologic complete response in patients with HR-positive, HER2-positive disease treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab with or without estrogen deprivation (Abstract S3-06).

Advertisement

Advertisement




Advertisement